Ben Perry, Discovery Open Innovation Leader at DNDi, is a medicinal chemist with over 20 years of experience conducting early-stage drug discovery across a variety of disease indications including oncology, autoimmune disorders, and psychiatry.

Prior to joining DNDi, Ben held research positions at the University of Colorado (US), Celltech and UCB (UK), Addex Pharmaceuticals and Genkyotex (Switzerland). His areas of research interest include the use of chemoinformatic and computational tools within medicinal chemistry, and the use of new technologies and research collaborations to further the drug discovery process, with a strong focus on neglected diseases and patient populations